1
EPISODE · May 25, 2026 · 17 MIN
FDA Approves First Non-Antipsychotic Drug For Dementia Agitation, Reshaping Treatment Options
from 1nessAgency Insights
On April 30, 2026, the FDA approved Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) for a new indication: treating agitation associated with Alzheimer's disease dementia in adults [1]. The approval is a first of its kind , no non-antipsychotic drug has ever carried this indicati
Embed this episode
NOW PLAYING
FDA Approves First Non-Antipsychotic Drug For Dementia Agitation, Reshaping Treatment Options
0:00
17:00
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of 1nessAgency Insights?
This episode is 17 minutes long.
When was this 1nessAgency Insights episode published?
This episode was published on May 25, 2026.
Can I download this 1nessAgency Insights episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!